NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CNSP Stock Alerts $0.22 +0.01 (+4.81%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.20▼$0.2250-Day Range$0.20▼$0.4552-Week Range$0.19▼$2.98Volume109,097 shsAverage Volume359,958 shsMarket Capitalization$2.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get CNS Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About CNS Pharmaceuticals Stock (NASDAQ:CNSP)CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More CNSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNSP Stock News HeadlinesApril 25, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024April 4, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate UpdateApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 3, 2024 | benzinga.comCNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and RevenueApril 2, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023March 20, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to BoardFebruary 9, 2024 | investing.comCns Pharmaceuticals Inc (CNSP)February 3, 2024 | msn.comCNS Pharmaceuticals Launches Public Offering for Trial FundingApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.January 30, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering PricingJanuary 29, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 29, 2024 | finance.yahoo.comCNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 19, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of DirectorsJanuary 18, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 18, 2024 | finance.yahoo.comBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 17, 2024 | finance.yahoo.comCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)January 6, 2024 | seekingalpha.comCNSP CNS Pharmaceuticals, Inc.December 18, 2023 | finance.yahoo.comCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of BerubicinDecember 14, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary SharesDecember 8, 2023 | msn.comCNS Pharmaceuticals files to sell 3.81M shares of common stockDecember 6, 2023 | finance.yahoo.comHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No CureNovember 22, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of EfficacyNovember 21, 2023 | msn.comCNS Pharmaceuticals files to sell 3.76M shares of common stock for holdersNovember 16, 2023 | finance.yahoo.comCNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug CandidateNovember 15, 2023 | finance.yahoo.comCNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year EndNovember 11, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary Shares CNSPOctober 19, 2023 | finance.yahoo.comCNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO ConferenceSee More Headlines Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNSP CUSIPN/A CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-603.40% Return on Assets-421.35% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-0.31Miscellaneous Outstanding Shares10,640,000Free Float10,222,000Market Cap$2.32 million OptionableNot Optionable Beta2.67 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John Michael Climaco Esq. (Age 55)J.D., CEO, President & Director Comp: $525kMr. Christopher S. Downs CPA (Age 46)CTP, FP&A, Chief Financial Officer Comp: $340kDr. Sandra L. Silberman M.D. (Age 69)Ph.D., Chief Medical Officer Comp: $200kDr. Waldemar Priebe Ph.D.FounderDr. Donald H. Picker Ph.D. (Age 78)Chief Science Officer Key CompetitorsDermata TherapeuticsNASDAQ:DRMANotable LabsNASDAQ:NTBLSalarius PharmaceuticalsNASDAQ:SLRXCyclacel PharmaceuticalsNASDAQ:CYCCClearmind MedicineNASDAQ:CMNDView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 122,000 shares on 2/13/2024Ownership: 1.965%Christopher DownsBought 27,000 shares on 8/22/2023Total: $34,290.00 ($1.27/share)John M ClimacoBought 2,750 shares on 8/16/2023Total: $4,950.00 ($1.80/share)View All Insider TransactionsView All Institutional Transactions CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed in 2024? CNS Pharmaceuticals' stock was trading at $1.27 on January 1st, 2024. Since then, CNSP stock has decreased by 82.8% and is now trading at $0.2180. View the best growth stocks for 2024 here. Are investors shorting CNS Pharmaceuticals? CNS Pharmaceuticals saw a drop in short interest in April. As of April 15th, there was short interest totaling 23,100 shares, a drop of 53.8% from the March 31st total of 50,000 shares. Based on an average trading volume of 415,800 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the shares of the company are sold short. View CNS Pharmaceuticals' Short Interest. When is CNS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CNSP earnings forecast. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) posted its quarterly earnings results on Monday, April, 1st. The company reported ($0.95) earnings per share (EPS) for the quarter. When did CNS Pharmaceuticals' stock split? Shares of CNS Pharmaceuticals reverse split on the morning of Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ). When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNSP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.